LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc., a publicly held biotechnology company, today announced that Phase I data on the Company’s prostate cancer drug CB7630 (abiraterone acetate) will be presented at National Cancer Research Institute (NCRI) Cancer Conference that will take place October 8-11, 2006 in Birmingham, UK.
